In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes - Journal of Materials Science: Materials in Medicine
Source : https://link.springer.com/article/10.1007/s10856-021-06623-6
In this study, paclitaxel (PTX)-loaded pH-responsive niosomes modified with ergosterol were developed. This new formulation was characterized in terms of size, morphology, encapsulation efficiency (EE), and in vitro release at...
Conclusion: Overall, our results provide proof of concept for encapsulating PTX in niosomal formulation to enhance its therapeutic efficacy.
Protective role of cytoplasmic p21Cip1/Waf1 in apoptosis of CDK4/6 inhibitor-induced senescence in breast cancer cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34761877/
Inhibition of CDK4/6 slows the cell cycle and induces senescence in breast cancer cells. However, senescent cancer cells promote invasion and metastasis. Several drugs reportedly target senescent cells, including ABT-263...
Conclusion/Relevance:These results suggest that cytoplasmic p21 plays a protective role in apoptosis of CDK4/6 inhibitor-induced senescent breast cancer cells.
Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34785661/
1 Institute of Structural Biology, University of Bonn, Bonn, Germany. 2 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. 3 Department of Biological Chemistry and Molecular Pharmacology, Harvard...
Conclusion/Relevance: Remarkably, DYRK1A is inhibited by abemaciclib to the same extent as Cdk4/Cdk6 in vitro, raising the question of whether targeting of DYRK1A contributes to the transcriptional inhibition and therapeutic activity of abemaciclib.
Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34751591/
Aim: To assess the relative impact of palbociclib plus fulvestrant (PAL + FUL) and abemaciclib plus fulvestrant (ABEM + FUL) on patient-reported outcomes in patients with hormone receptor-positive, HER2-negative (HR+/HER2-)...
Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement
Source : https://www.mdpi.com/2072-6694/13/22/5643
Purpose of review: Due to the findings of current studies and the approval of novel substances for the therapy of hormone-receptor-positive breast cancer patients, the established standards of endocrine treatment...
Conclusion/Relevance:Considering signaling pathways such as the PI3K/AKT/mTOR or the CDK4/6 pathway, as well as resistance mechanisms and substances analyzed against these, endocrine treatment of hormone-receptor-positive breast cancer is on the brink of a new era. This review provides an overview of the history of endocrine treatment, clarifies...